Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Encorafenib

FDA-approved product (capsule, oral), marketed as Braftovi.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Encorafenib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Colorectal adenocarcinoma
  • Colorectal cancer
  • Colorectal neoplasm
  • Cutaneous melanoma
  • Melanoma
  • Metastatic melanoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
B-raf serine-threonine kinase (braf) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Encorafenib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Encorafenib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

    NCT01909453 · start 2013-09-12

    Registered record
    Registry ID
    NCT01909453
    Conditions
    Melanoma
    Interventions
    LGX818; MEK162; vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09-12
    Completion
    2024-09-03
    Enrolment
    921

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionLGX818; MEK162; vemurafenib
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

    NCT01777776 · start 2013-07

    Registered record
    Registry ID
    NCT01777776
    Conditions
    Locally Advanced Metastatic BRAF Mutant Melanoma
    Interventions
    LEE011; LGX818
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2013-07
    Completion
    2015-04
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Metastatic BRAF Mutant Melanoma
    InterventionLEE011; LGX818
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

    NCT01719380 · start 2012-11-23

    Registered record
    Registry ID
    NCT01719380
    Conditions
    Colorectal Cancer
    Interventions
    LGX818; Cetuximab; BYL719
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-11-23
    Completion
    2019-02-12
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionLGX818; Cetuximab; BYL719
    PhasePhase 2
    Registry statusCompleted

  • A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

    NCT01543698 · start 2012-05-28

    Registered record
    Registry ID
    NCT01543698
    Conditions
    Solid Tumors Harboring a BRAF V600 Mutation
    Interventions
    LGX818; MEK162; LEE011
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2012-05-28
    Completion
    2023-03-09
    Enrolment
    189

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors Harboring a BRAF V600 Mutation
    InterventionLGX818; MEK162; LEE011
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

    NCT01519427 · start 2012-01

    Registered record
    Registry ID
    NCT01519427
    Conditions
    Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
    Interventions
    Akt inhibitor MK2206; selumetinib; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-01
    Completion
    2013-05
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma +1 more
    InterventionAkt inhibitor MK2206; selumetinib; laboratory biomarker analysis
    PhasePhase 2
    Registry statusTerminated